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It has become clear that apoptosis (Kerr et al, 1971), programmed
cell death, is related to various diseases (Matsuno et al, 1994;
Dowling et al, 1996; Giordano et al, 1997; Strater et al, 1997). It
occurs even in carcinoma cells as a common process of cell death,
although immortality is one of the important characters of carci-
noma cells (Barry et al, 1990; Ling et al, 1993; Tauchi and
Sawada, 1994). This has led to intensive study of apoptosis in
carcinoma by various approaches. For the mechanism mediating
apoptosis, the Fas-Fas ligand (Fas L) (Itoh et al, 1991: Suda et al,
1993) pathway is a prominent candidate. Fas belongs to the
tumour necrosis factor receptor family (MW45000) (Itoh et al,
1991: Oehm et al, 1992) and is expressed in various carcinoma
cells and cell lines as well as in many normal human cells (Falk
et al, 1992; Leithauser et al, 1993: Yoshino et al, 1994). Fas L
belongs to the tumour necrosis factor family (MW40000) (Suda et
al, 1993; Suda and Nugata, 1994) and is normally expressed by 
T lymphocytes when they are activated. The signal for cell death is
thus transmitted when Fas L binds to Fas on the target cell
(Rouvier et al, 1993; Kagi et al, 1994).
The liver is one of the organs which constitutively expresses Fas
(Leithauser et al, 1993) and Fas-mediated apoptosis seems to play
an important role in inflammation in chronic hepatitis (Hiramatsu
et al, 1994; Mochizuki et al, 1996). Furthermore, we previously
investigated Fas expression in hepatocellular carcinoma (HCC)
and found that, although Fas was expressed in HCC with a high
incidence rate, cases with poor differentiation more frequently
lacked Fas immunoreactivity (Ito et al, 1998). These findings
suggest that the possibility of apoptotic cell death of HCC cells by
attack from T lymphocytes via Fas L decreases with the biological
aggressiveness of HCC.
Strand et al (1996) investigated Fas L expression in HCC by
means of in vitro and in vivo studies. They found that Hep G2
cells, a hepatoma cell line, under stimulus of bleomycin to express
Fas L, induced apoptosis of co-cultured Jurkat cells sensitive to
Fas-mediated apoptosis, although this event was not observed
using Hep G2 cells which do not have the stimulus are negative for
Fas L. Furthermore, Jurkat cells plated on cryosections from HCC
tissues positive for Fas L mRNA died by apoptosis, whereas they
did not turn apoptotic on sections from Fas L mRNA-negative
HCC (Strand et al, 1996). These findings indicate that HCC cells,
as well as stromal lymphocytes, can express functional Fas L to
counterattack and kill the lymphocytes. It is therefore suggested
that Fas L, as well as Fas, is an important factor for evaluating the
biological aggressiveness of HCC.
All these observations prompted us to investigate the expression
of Fas L, as well as Fas, in a large number of HCC to elucidate
their clinical significance including their prognostic value. In this
study, we investigated the expression of Fas L expression in
stromal mononuclear cells and in HCC cells, as well as Fas expres-
sion in HCC cells for 103 cases.
MATERIALS AND METHODS
Cell lines and tissue specimens
The human colon carcinoma cell line SW480 and pancreatic carci-
noma cell line AsPc-1 were provided by the Japanese Cancer
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medium supplemented with 10% fetal calf serum (FCS) at 37°C in
5% carbon dioxide. Tissue specimens were obtained from 103
patients who had undergone surgery for solitary HCC and three
patients for breast carcinoma. The tissues were fixed overnight
with 10% buffered formalin. After being washed for over 1 h with
water and dehydrated through a graded ethanol series at 4°C, the
tissues were immersed three times in xylene pools and four times
in paraffin pools and embedded in paraffin. The patient profiles
are presented in Table 1. Informed consent was obtained from each
patient. Four-micrometre-thick sections for each block were
prepared for immunohistochemical examination.
Antibodies
Two kinds of primary antibodies were used in this study. Anti-Fas
monoclonal antibody (clone CH-11), the specificity of which had
been established previously (Hiramatsu et al, 1994; Mochizuki et
al, 1996), was obtained from MBL (Nagoya, Japan). Anti-Fas L
polyclonal antibody was from Nichirei (Tokyo, Japan). This anti-
body specifically recognizes synthetic peptides of the 41st to 54th
amino acids located in the intracellular domain of human Fas L.
The final dilutions of the primary antibodies were 2.5 mg ml–1 and
10 mg ml–1, respectively.
Immunohistochemical procedure
Cultured cells were collected, cytocentrifuged onto poly-L-lysine-
coated glass slides, immediately fixed in buffered formalin for 1 h,
and washed in distilled water for 5 min. Tissue sections were
prepared from 4-mm-thick slices from paraffin-embedded speci-
mens. The paraffin was removed in xylene three times, after which
the tissues were rehydrated through a graded ethanol series
ranging from 100% to 60%.
Endogenous peroxidase activity was blocked with 0.3%
hydrogen peroxide (H2O2) and 0.1% sodium azide in distilled
water for 20 min. After three rinsings in phosphate-buffered saline
(PBS) pH 7.2, 10% normal rabbit serum (Nichirei, Tokyo, Japan)
for anti-Fas antibody or goat serum (Nichirei, Tokyo, Japan) for
anti-Fas L antibody was applied for 30 min to block the non-
specific reaction. Sections were incubated with anti-Fas antibody
or anti-Fas L antibody overnight at 4°C. After rinsing in PBS, they
were treated with biotinylated rabbit anti-mouse immunoglobulins
(Nichirei, Tokyo, Japan) for anti-Fas or biotinylated goat anti-
rabbit IgG (Nichirei, Tokyo, Japan) for anti-Fas L for 30 min.
Again after rinsing in PBS, the sections were allowed to react with
the avidin–biotin peroxidase complex (Nichirei, Tokyo, Japan).
The peroxidase reaction was visualized by incubating the sections
with 0.02% 3,3¢-diaminobenzidine tetrahydrochloride in 0.05 M
Tris buffer (pH 7.6) with 0.01% H2O2 for 4 min. The sections were
counterstained with haematoxylin. Sections for negative control
were prepared by using normal mouse serum instead of primary
antibody.
The newly established anti-Fas L antibody was subjected to an
absorption test to investigate its specificity. The antibody was
reacted with a synthetic peptide that this antibody recognizes
(final concentration, 50 mg ml–1) at room temperature overnight.
Thereafter, the reactant was applied to the sections as primary anti-
body in an immunohistochemical procedure.
Immunohistochemical evaluation
We classified the immunohistochemical results into three groups
based on Fas expression: ++, more than 80% of HCC cells were
clearly positive; +, 10–80% of the cells were positive; –, less than
10% of the cells were positive. To evaluate Fas L expression in the
stroma, we observed at least ten fields randomly under a light
microscope at ´ 400 magnification and counted the Fas L-positive
cells. The average of the number of Fas L-expressing mononuclear
cells per field was defined as the stromal Fas L index. In each case,
we carefully checked whether Fas L was expressed in the HCC
cells.
Each of these three factors only partially reflects the status of the
Fas-Fas L pathway. Therefore, for total evaluation, we scored each
factor as follows: (1) Fas (++) or (+) cases were scored as 0 and Fas
(–) cases were scored as 1; (2) if the stromal Fas L index was ³ 2.0,
the case was scored as 0, and if < 2.0, it was scored as 1; (3) if Fas
L-expressing carcinoma cells were observed, the case was scored
as 1, and otherwise, scored as 0. The total amount of the scores for
these three factors is named the ‘Fas-Fas L risk score’.
Survival data
Disease free survival (DFS) data of the 83 patients who underwent
curative surgery were analysed. They were followed up from 5 to
73 months (mean 21.0 months). Post-operative DFS curves were
constructed by the Kaplan–Meier method.
Statistical analyses
The values were expressed as mean ± s.e.m. The c2 test and
Student’s t-test were employed for analyses of the immunohisto-
chemical data and clinicopathological parameters such as age,
gender, tumour size, liver cirrhosis, TNM stage, degree of
differentiation, capsule formation, extracapsular invasion, septal
formation, portal invasion and intrahepatic metastasis. Various
pathological classifications including degrees of differentiation
and stage were based on the classification of the Liver Cancer
Group of Japan (1992). Portal invasion and intrahepatic metastasis
were histologically diagnosed. Univariate survival data were
analysed by the log-rank test. For multivariate analyses for DFS
data, we used the Cox proportional hazard model. All P-values
less than 0.05 were considered to be statistically significant.
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Table 1 Profile of the 103 HCC cases used in this study
Age (years) 62.6 ± 10.5
Size (cm) 3.8 ± 2.2
Gender
Male 89
Female 14
HCV Ab (+/–) 70/27 (unknown 6)
HBs Ag (+/–) 17/86
Liver cirrhosis (+/–) 67/36
Portal invasion (+/–) 34/69
Intrahepatic metastasis (+/–) 23/80
Carcinoma differentiation
Poor 23
Moderate 61
Well 19
Stage 36
67
³III
<IIIRESULTS
Fas expression was diffusely or heterogeneously observed in the
cell membranes and the cytoplasms of hepatocytes in non-
cancerous lesions which were diagnosed as having chronic active
or inactive hepatitis with or without liver cirrhosis as well as bile
ducts (Figure 1A) and infiltrating mononuclear cells (data not
shown). No correlation could be established between Fas expres-
sion and various characteristics such as viral infection, active or
inactive hepatitis and with or without liver cirrhosis (data not
shown). Fas was also expressed in various degrees in HCC cells
(Figure 1B). We investigated the relationship between Fas expres-
sion in HCC and various clinicopathological parameters. As a
result, the absence of or decreased Fas expression in HCC cells
was observed significantly more frequently in cases with poor
differentiation (Figure 1C) (P < 0.0001) and of larger size (P =
0.0058) as shown in Table 2.
For the immunohistochemical observation, we used SW480
cells, a colon carcinoma cell line, and AsPc-1 cells, a pancreatic
carcinoma cell line as positive controls of Fas L (Figure 2A, B)
(Shiraki et al, 1997; von Bernstorff et al, 1999). As negative
controls, we employed human breast and liver tissues (Xerri et al,
1997) and confirmed that gland epithelial and myoepithelial cells
of mammary glands and hepatocytes were immunohistochemi-
cally negative for Fas L (data not shown).
We then investigated Fas L expression in the 103 HCC cases.
Fas L immunoreactivity was observed in various degrees in
membranes as well as the cytoplasms of the infiltrating mono-
nuclear cells in the stroma adjacent to the carcinoma nests (Figure
2C, D). Infiltrating mononuclear cells were also observed in the
non-cancerous portal areas but were only occasionally positive for
Fas L (Figure 2E). The stromal Fas L index of each case ranged
from 0 to 22.7 (mean ± s.e.m: 2.8 ± 3.8) and was not related to any
clinicopathological parameter. Furthermore, Fas L was expressed
also in carcinoma cells in 20 of the 103 cases we examined (Figure
2F,G). Sixteen of them were moderately differentiated and the
remaining four were poorly differentiated carcinomas (Table 2).
Well differentiated carcinomas in our series were all negative for
Fas and Fas ligand in hepatocellular carcinoma 1213
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Figure 1 Immunostaining of Fas. (A) Fas expression in noncancerous
hepatocytes and bile duct. Fas was diffusely expressed by hepatocytes and
bile ductular cells. (B) Fas expression in HCC. This moderately differentiated
carcinoma diffusely expressed Fas and almost all carcinoma cells were
positive for Fas in this area. (C) This poorly differentiated carcinoma did not
express Fas. Scale bars: 20 mm
Table 2 Relationship between the factors investigated in this study and
clinicopathological parameters
1. Fas expression
++ + – Total P-values
Tumour size (cm) 3.4±1.9 3.8±4.8 5.0±2.9 0.0058
Differentiation
Well 15 4 0 19
Moderate 40 17 4 61 < 0.0001
Poor 1 5 17 23
2. Fas L-expressing carcinoma cells
+ – Total P-value
Differentiation
Well 0 19 19
Moderate 16 45 61 0.0398
Poor 4 19 19
3. Fas-Fas L risk score
01 ³ 2 Total P-value
Differentiation
Well 5 14 0 19
Moderate 23 27 11 61 < 0.0001
Poor 3 5 15 231214 Y Ito et al
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Figure 2 Immunostaining for Fas L. Signal for Fas L was observed in
SW780 cells (A) and AsPc-3 cells (B). (C, D) Fas L was expressed in
mononuclear cells infiltrating around the carcinoma nest. (E) Fas L was
occasionally positive in mononuclear cells in the portal area in noncancerous
lesions. The arrows indicate cells positive for Fas L. (F, G) Fas L was
heterogeneously expressed in HCC cells in these poorly differentiated
carcinomas. The arrows indicate cells positive for Fas L in F. Fas L was
more diffusely positive in G. Scale bars: A, B = 10 mm; C, D, E = 20 mm;
F, G = 16 mmFas L in carcinoma cells. No other relationships could be estab-
lished between the above three factors and clinicopathological
features in our series (data not shown).
In the second phase of our study, we investigated the prognostic
value for DFS for each of the above three factors by the
Kaplan–Meier method. As a result, all three factors, Fas (P <
0.0001), stromal Fas L index (P = 0.0027) and the presence of Fas
L-expressing carcinoma cells (P = 0.0222), showed the prognostic
impact for DFS by the log-rank test (Table 3).
In order to evaluate the status of Fas and Fas L expression in
each case, we defined the Fas-Fas L risk score as mentioned
above. The higher the score is, the less likely it would be that the
carcinoma cells die with Fas-mediated apoptosis. As shown in
Table 1, the score was significantly higher (P < 0.0001) in poorly
differentiated carcinomas. Furthermore, patients with a score of 1
or ³ 2 were much more likely to show recurrence (P < 0.0001)
than those with a score of 0 (Figure 3).
We also performed multivariate analysis using the Cox propor-
tional hazard model for DFS (Table 3), together with other para-
meters which showed the prognostic value for DFS by univariate
analyses in our series. As a result, all the three factors, Fas expres-
sion in carcinoma cells (P = 0.0156), stromal Fas L index (P =
0.0453) and Fas L expression in carcinoma cells (P = 0.0255)
could be regarded as independent prognostic markers for DFS. We
then analysed the Fas-Fas L risk score, instead of the three factors
by multivariate analyses, with a result that it showed much
stronger prognostic impact than the three factors (P < 0.0001 vs
0.0156, 0.0453 and 0.0255). Although the score was strongly
Fas and Fas ligand in hepatocellular carcinoma 1215
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Table 3 Univariate and multivarate analyses of various parameters for disease-free survival of HCC patients
P-values
Parameters Univariate Multivariate
Stage (> III vs ≤ III) < 0.0001 0.0001 0.0013
Tumour size
(³ 5 cm vs < 5 cm) 0.0392 0.0314 0.0768
Differentiation
(well, moderate vs poor) 0.0027 0.9141 0.2289 0.0690
Portal thrombus 0.0181 0.6653 0.2309
Intrahepatic metastasis 0.0001 0.0520 0.2289
Fas expression (++, + vs –) < 0.0001 0.0156 0.0003
Stromal Fas L index 0.0027 0.0453 0.0241
(³ 2.0 vs < 2.0)
Fas L in carcinoma cells 0.0222 0.0255 0.0396
Fas-Fas L risk score < 0.0001 < 0.0001 0.0001 0.0001
(0 vs ³ 1)
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Figure 3 Disease-free survival curve of 83 patients with Fas-Fas L risk score 0, 1 and ³ 2 following curative surgerycorrelated with carcinoma differentiation, it was recognized as a
prognostic value independent of carcinoma differentiation,
because, when it was analysed with carcinoma differentiation, its
P-value was 0.0001, whereas that of carcinoma differentiation was
over 0.05 (Table 3). Furthermore, when the score was analysed
with the clinical stage, its P-value was 0.0001, showing that it
could be regarded as an independent prognostic factor together
with the clinical stage.
DISCUSSION
We found that non-cancerous hepatocytes, all of which were diag-
nosed as chronic hepatitis with or without liver cirrhosis, as well as
bile ducts very often expressed Fas antigen. Those results are very
similar to those of previous studies using the same antibody
(Hiramatsu et al, 1994; Mochizuki et al, 1996). Regarding HCC,
this and our previous studies (Ito et al, 1998) demonstrated that the
absence of or decreased Fas expression in HCC cells was observed
significantly more frequently in cases with poor differentiation.
Furthermore, cases with lack of Fas expression showed poorer
outcomes for DFS. These findings strongly suggest that HCC cells
in biologically aggressive cases would less likely die by apoptosis
via Fas L, because of their lack of Fas expression in whole or part.
Similar results have been reported for lung carcinoma by a
previous study with a similar approach (Koomagi and Volm,
1999).
Our immunohistochemical finding that Fas antigen is localized
at both the cell surface and cytoplasm agrees with those of studies
on Fas-transfected COS cells (Cheng et al, 1994) as well as on the
liver using the same antibody (Hiramatsu et al, 1994; Mochizuki et
al, 1996). Fas expression in HCC has been investigated using
another antibody by other groups but their results did not show
mutual agreement (Higaki et al, 1996; Terada and Nakanuma,
1996).
The staining profile of Fas L in each cell should be supported by
an absorption test and a recent study demonstrating the presence of
Fas L in the cytoplasms of human peripheral monocytes by means
of different approaches (Kiener et al, 1997). In our study, Fas L
expression in mononuclear cells did not show correlation with any
clinicopathological features of HCC, but cases with Fas L expres-
sion displayed much better outcomes for DFS. Although further
studies are needed to determine whether Fas L expressed by
mononuclear cells is always functional, our discovery of the prog-
nostic value of this factor leads to the speculation that Fas L-
expressing mononuclear cells act against HCC progression by
killing Fas-expressing HCC cells regardless of the characteristics
of the carcinoma.
We demonstrated that Fas L was also expressed in HCC cells, in
agreement with the findings of other investigators on other carci-
nomas (Niehans et al 1997; Gratas et al, 1998; Koomagi and Volm,
1999; Loro et al, 1999; Olive et al, 1999; Peduto Eberl et al, 1999;
von Benstorff et al, 1999). Regarding the function of Fas L
expressed by carcinoma cells, previous in vitro studies using
various carcinoma cell lines revealed that it plays a role in counter
attacking and killing the activated Fas-sensitive T-cells
(O’Connell et al, 1996; Strand et al, 1996; von Bernstorff et al,
1999). Furthermore, Strand et al proved that HCC tissues can
express functional Fas L because Jurkat cells sensitive to Fas-
mediated apoptosis were killed when they were plated on cryosec-
tions from Fas L mRNA expressing HCC (Strand et al, 1996). Our
study showed that HCC cases with Fas L-expressing carcinoma
cells belonged to moderately or poorly differentiated but not well
differentiated carcinomas, and that such cases were significantly
more likely to show recurrence. These findings led us to suggest
that Fas L expressed by HCC cells is, at least in part, functional
and increases the biological aggressiveness of HCC by counter-
attacking the stromal lymphocytes.
We defined the Fas-Fas L risk score to totally evaluate the three
independent factors: whether HCC cells express Fas, whether the
stromal mononuclear cells express Fas L and whether HCC cells
express Fas L. Our results indicate that the score accurately
reflects the DFS of the patients. In multivariate analysis with carci-
noma differentiation, the P-value of this score was 0.0001, in spite
of being significantly related to carcinoma differentiation, indi-
cating that the prognostic value of this score is not dependent on
the characteristics of the carcinoma differentiation. Furthermore,
when we performed the analysis at the clinical stage, the P-value
was also 0.0001 and even lower than that of clinical stage, leading
us to conclude that the evaluation of Fas and Fas L expression in
HCC tissue can be a novel predictor of recurrence of HCC patients
in addition to the clinical stage.
Another interesting and important subject is whether apoptosis
in HCC is dominantly induced by the Fas-Fas L pathway. If it is,
then we should be able to evaluate the above-mentioned character-
istics simply by investigating the apoptotic cell rate in each case.
However, a previous study demonstrated that there is no signifi-
cant relationship between the apoptotic cell rate and the status of
Fas and Fas L expression in HCC (Kubo et al, 1998) and we also
obtained a similar result (data not shown). Far from that, it has
been reported that apoptotic cell rate should reflect the biological
aggressiveness of carcinoma including poor prognosis in HCC (Ito
et al, 1999) as well as the carcinoma of several organs (Lipponen
and Aultomaa, 1994; Vasaslainen et al, 1994; Heatley, 1995;
Tormanen et al, 1995; Todd et al, 1996; Yamasaki et al, 1997;
Komaki et al, 1998). We therefore hypothesized that there are at
least two types of apoptosis in carcinoma. One is an epiphenom-
enon of the rapid progression of carcinoma, possibly due to the
rapid turnover of carcinoma cells. Another is derived from the
signal of cell death mainly from the Fas-Fas L pathway. Our
results suggest that Fas-mediated apoptosis is not dominant in
HCC, although it can be an important phenomenon for evaluating
the biological characteristics and prognosis of this carcinoma.
In summary, we have shown that the status of Fas and Fas L
expression definitely reflects HCC progression and can serve an
independent prognostic factor for DFS of HCC patients. This
phenomenon may be useful for future clinical anticancer therapy.
For example, stimulating lymphocytes to express Fas L and/or
forcing carcinoma cells to express Fas could inhibit HCC progres-
sion and reduce the possibility of recurrence.
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